Madrigal Pharmaceuticals Inc
MDGL
查看详细走势图
495.910USD
-3.260-0.65%
交易中 （美东）报价延迟15分钟
11.26B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.65%
5天
-1.15%
1月
-17.20%
6月
+66.19%
今年开始到现在
-14.84%
1年
+51.13%
查看详细走势图
TradingKey Madrigal Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-01-26操作建议
Madrigal Pharmaceuticals Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名22/394位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价628.40。中期看，股价处于上升通道。近一个月，市场表现非常差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Madrigal Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Madrigal Pharmaceuticals Inc亮点
亮点风险
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
利润高增长
公司净利润处于行业前列，最新年度总收入180.13M美元
估值低估
公司最新PE估值-38.66，处于3年历史低位
机构减仓
最新机构持股21.93M股，环比减少9.21%
景顺投资公司持仓
明星投资者景顺投资公司持仓，最新持仓市值24.48K
分析师目标
根据
16
位分析师
买入
评级
415.786
目标均价
+25.53%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Madrigal Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Madrigal Pharmaceuticals Inc简介
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
公司代码MDGL
公司Madrigal Pharmaceuticals Inc
CEOSibold (Bill)
网址https://www.madrigalpharma.com/
相关品种
